Retatrutide Research: Reading the Phase 2 Weight and Liver-Fat Studies

Retatrutide activates GIP, GLP-1 and glucagon receptors. Its phase 2 programme investigated body weight, blood glucose and liver fat, but these outcomes should not be collapsed into a single claim that it improves every aspect of metabolic health. Reading the original papers makes it possible to distinguish the observed changes from the questions that remained unanswered. [1–3]

This article focuses on the published phase 2 studies from 2023 and 2024. It is a study explainer, not a complete review of the later development programme or a statement about current access. A subsequent phase 3 TRIUMPH-2 publication is linked for readers following the programme beyond this scope. [4]

The 338-participant obesity study

The 2023 New England Journal of Medicine trial randomised 338 adults with obesity, or overweight plus a weight-related condition, to retatrutide or placebo. The primary endpoint was percentage change in body weight at 24 weeks, with follow-up extending to 48 weeks. At 48 weeks, the highest-dose group had an estimated mean weight reduction of 24.2%, compared with 2.1% in the placebo group. [1]

These are group estimates in a monitored trial, not a forecast for every individual. The most common adverse events were gastrointestinal, and the paper also reported increases in heart rate that peaked during follow-up and later declined. Reporting the weight result without the adverse-event findings gives an incomplete account of the experiment.

The diabetes trial asked a different primary question

A separate phase 2 trial enrolled 281 people with type 2 diabetes and included both placebo and an active dulaglutide comparator. Its primary endpoint was change in HbA1c at 24 weeks. Several retatrutide groups showed greater reductions than placebo, while some also exceeded the particular dulaglutide regimen studied. Body-weight changes were additional outcomes. [2]

An active comparator is useful because it asks more than whether a compound differs from placebo. However, the comparison applies to the regimens and population actually tested. It cannot establish superiority over every medicine in a class, nor can results in people with diabetes be assumed to describe an otherwise healthy population.

Liver-fat reductions: a substudy rather than a separate confirmation

The 2024 liver-fat paper analysed 98 participants from the obesity trial who had metabolic dysfunction-associated steatotic liver disease and at least 10% liver fat. At 24 weeks, higher retatrutide groups showed large relative reductions in measured liver fat compared with placebo. These changes were associated with changes in body weight and other metabolic measures. [3]

Because this was a subset of the parent trial, it should not be counted as wholly independent replication. A relative reduction in liver fat also differs from an absolute percentage-point reduction. Neither measure by itself demonstrates prevention of liver failure or reversal of every feature of liver disease. The endpoint and its units matter as much as the headline percentage.

What these studies leave open

The phase 2 publications provide human evidence for specific metabolic changes under their study conditions. They do not establish that a research-labelled product has the identity, manufacturing controls or clinical performance of the investigational medicine. Nor do they provide a basis for designing a personal regimen from a summary article.

When reading later work, compare participant characteristics, follow-up length, missing data, adverse events and the prespecified endpoints. Longer-term clinical outcomes require their own evidence; a large change in a biomarker or body weight is not a substitute for measuring them. Bali Peptide Lab has a commercial interest as a research-material supplier. This article, prepared on 22 October 2026, is educational and does not recommend human use of its catalogue materials.